Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to enable effective delivery across the blood-brain barrier, targeting challenging central nervous system disorders. Its pipeline includes programs like DNL310 (Tividenofusp alfa) for Hunter syndrome (MPS II), DNL126 for MPS IIIA (Sanfilippo Syndrome A), DNL343 (eIF2B activator) for amyotrophic lateral sclerosis, BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease, Eclitasertib (DNL758, RIPK1 inhibitor) for peripheral inflammatory diseases, and others such as TAK-594/DNL593 for frontotemporal dementia-granulin and initiatives targeting TREM2 and Tau. Denali Therapeutics Inc. advances these candidates through clinical development, emphasizing innovative solutions for unmet needs in neurology and rare genetic disorders. Founded in 2013 and headquartered in South San Francisco, California, it plays a key role in the biotechnology sector dedicated to neurodegeneration.